Seroprevalence study of HCV among hospitalized intravenous drug users in Ahvaz, Iran (2001-2006)

Journal of Infection and Public Health

Volumn 2, Issue 1, 2009, Pages 47-51

  Alavi, Seyed Mohammad ^a   Alavi, Leila ^a  

^a AHVAZ JUNDISHAPUR UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Ahvaz; Hepatitis C virus; Intravenous drug user; Seroprevalence

Indexed keywords

HEPATITIS C ANTIBODY;

ADULT; ARTICLE; COMPUTER PROGRAM; EDUCATIONAL STATUS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GEOGRAPHIC PATHOLOGY; HEPATITIS B; HEPATITIS C; HOSPITAL PATIENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ABUSE; IRAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PRISON; RESIDENTIAL AREA; SEROPREVALENCE; SEX DIFFERENCE; SOCIOECONOMICS;

ADULT; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPACIVIRUS; HEPATITIS C; HEPATITIS C ANTIBODIES; HOSPITALIZATION; HOSPITALS, TEACHING; HUMANS; IRAN; MALE; MEDICAL RECORDS; MIDDLE AGED; PRISONERS; RETROSPECTIVE STUDIES; RISK FACTORS; SEROEPIDEMIOLOGIC STUDIES; SUBSTANCE ABUSE, INTRAVENOUS; YOUNG ADULT;

EID: 61849175957     PISSN: 18760341     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jiph.2009.01.001     Document Type: Article

References (22)

1. Razzaghi E.M., Movaghar A.R., Green T.C., and Khoshnood K. Aqualitative study of injecting drug user's in Tehran, Iran. Harm Reduct J 18 3 (2006) 12
2. Thomas D.L., Ray S.C., and Lemon S.M. In: Mandell G.L., Bennett J.E., and Dolin R. (Eds). Principle and practice of infectious diseases. 6th ed. (2005), Churchill Livingstone, USA, Philadelphia 1950-1981
3. Prevention Department of Welfare Organization. A summary report of drug related infectious disease in Iran; 2000.
4. Asadi S., and Marjani M. Prevalence of intravenous drug use-associated infections. Iran J Clin Infect Dis 1 2 (2006) 59-62
5. Carmo R.A., Oliveira G.C., Guimaraes M.D., Oliveira M.S., Lima A.A., Buzek S.C., et al. Hepatitis C virus infection among Brazilian hemophiliacs: a virological, clinical and epidemiological study. Braz J Med Biol Res 35 (2002) 589-598
6. Choo Q.L., Kuo G., Weiner A.J., Overby L.R., Bradley D.W., and Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 244 (1989) 359-362
7. Wharfe G., Smikle M., Dowe G., Buchner L., Choo-Kang E., Graham S., et al. Seroprevalence of hepatitis C virus in haemophiliacs in Jamaica. Hum Antibodies 11 (2002) 61-64
8. Alavian S.M. Control of hepatitis C in Iran: vision and missions. Hepatitis Mon 7 2 (2007) 57-58
9. Alavi S.M., and Etemadi A. HIV/HBV, HIV/HCV AND HIV/HTLV-1 co infection among injecting drug user patients hospitalized at the infectious disease ward of a training hospital in Iran. Pak J Med Sci 24 2 (2007) 358-360
10. Samuel M.C., Doherty P.M., Bulterys M., and Jenison S.A. Association between heroin use, needle sharing and tattoos received in prison with hepatitis B and C positivity among street-recruited injecting drug users in New Mexico, USA. Epidemiol Infect 127 (2001) 475-484
11. Zali M.R., Aghazadeh R., and Nowroozi A. Anti-HCV antibody among Iranian IV drug users: is it a serious problem?. Arch Iran Med 4 (2001) 115-119
12. Alizadeh A.H., Alavian S.M., Jafari K., and Yazdi N. Prevalence of hepatitis C virus infection and its related risk factors in drug abuser prisoners in Hamedan, Iran. World J Gastroenterol 11 (2005) 4085-4089
13. Hernandez-Aguado I., Ramos-Rincon J.M., Aviñio M.J., Gonzalez-Aracil J., Pérez-Hoyos S., de la Hera M.G., et al. Measures to reduce HIV infection have not been successful to reduce the prevalence of HCV in intravenous drug users. Eur J Epidemiol 17 6 (2001) 539-544
14. Judd A., Hutchinson S., Wadd S., Hickman M., Taylor A., Jones S., et al. Prevalence of, and risk factors for, hepatitis C virus infection among recent initiates to injecting in London and Glasgow: cross sectional analysis. J Viral Hepat 12 6 (2005 Nov) 655-662
15. Orton S.L., Stramer S.L., Dodd R.Y., and Alter M.J. Risk factors for HCV infection among blood donors confirmed to be positive for the presence of HCV RNA and not reactive for the presence of anti-HCV. Transfusion 44 2 (2004 Feb) 275-281
16. Moses S., Mestery K., Kaita K.D., and Minuk G.Y. Viral hepatitis in a Canadian street-involved population. Am J Public Health 93 2 (2002) 123-128
17. Caiaffa W.T., Mingoti S.A., Proietti F.A., Carneiro-Proietti A.B., Silva R.C., Lopes A.C., et al. Estimation of the number of injecting drug users attending an outreach syringe-exchange program and infection with human immunodeficiency virus (HIV) and hepatitis C virus: the AjUDE-Brasil project. J Urban Health 80 March(1) (2003) 106-114
18. Jahani M.R., AlavianSM, Shirzad H., Kabir A., and Hajarizadeh B. Distribution of risk factors HBV, HCV and HIV infection in female population with illegal social behavior. Sex Transm infect 81 (2005) 185-188
19. Merino C.E., Orozco J.A., Rojo M.A., and Tour A. Prevalence of hepatitis C virus among candida for blood donation at the general hospital in the Mexico. In Vivo 8 (1994) 621-623
20. Hahn JA, Page-Shafer K, Lum PJ, Bourgois P, Stein E, Evans JL, et al. Hepatitis C virus seroconversion among young injection drug users: relationships and risks. J Infect Dis 2002, 1;186(11):1558-64.
21. Stark K., Bienzle U., Vonk R., and Guggenmoos-Holzmann I. History of syringe sharing in prison and risk of hepatitis B virus, hepatitis C virus, and human immunodeficiency virus infection among injecting drug users in Berlin. Int J Epidemiol 26 6 (1997) 1359-1366
22. Sabbatani S., Giuliani R., Fulgaro C., Paolillo P., Baldi E., and Chiodo F. HIVAb, HCVAb and HBsAg seroprevalence among inmates of the prison of Bologna and the effect of counseling on the compliance of proposed tests. Epidemiol Prev 28 3 (2004) 163-168